Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bruin Biometrics
Los Angeles, California, United Statessem-scanner.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Commercial
01
Overview
Bruin Biometrics has commercialized the Provizio SEM Scanner, a non-invasive medical device for early detection of increased risk of pressure injuries. The technology is FDA-cleared (de novo authorization in 2018), CE-marked since 2013, and distributed globally through partnerships. Clinical data support its ability to detect sub-clinical tissue changes before visible skin damage occurs, enabling earlier intervention to prevent pressure injuries[1][2][3].
- Therapeutic areas
- Dermatology
- Modalities
- DeviceDigital tool/platform
- Industry
- Physiological Monitoring
02
Partnerships
Arjo (global distribution arrangement/investment partner)
Beyond the preview
Go deeper on Bruin Biometrics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bruin Biometrics.